Pulmonx Corporation (LUNG)
Summary
Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?
After reaching an important support level, Pulmonx Corporation (LUNG) could be a good stock pick from a technical perspective. LUNG recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year
Pulmonx NASDAQ: LUNG is rebuilding its sales organization, targeting a return to growth and preparing for potential commercialization of its AeriSeal therapy outside the United States in the second half of next year, President and CEO Glen French said during a Canaccord fireside chat.
What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now?
Does Pulmonx Corporation (LUNG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Pulmonx Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 143 | $184 | $265.26 | $81.26 | 44.16% |
 Bobby Adusumilli SJS Investment Consulting Inc. | 9 | $11.61 | $16.92 | $5.31 | 45.74% |
 Dinan Hu R Squared Ltd | 27,429 | $35,459.78 | $51,703.66 | $16,243.88 | 45.81% |
| KJ Ken Joseph Braidwel LLP | 752,541 | $6.34M | $1.71M | -$4.63M | -73.01% |
 Drew Phillips Fortitude Family Office LLC | 90 | $117 | $166.5 | $49.5 | 42.31% |
Pulmonx Corporation (LUNG) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pulmonx Corporation ever had a stock split?
Pulmonx Corporation Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Glendon E. French CEO | NASDAQ (NGS) Exchange | 745848101 CUSIP |
| US Country | 296 Employees | - Last Dividend | - Last Split | 1 Oct 2020 IPO Date |
Overview
Pulmonx Corporation, initially known as Pulmonx, is a commercial-stage medical technology company that specializes in creating minimally invasive devices aimed at treating chronic obstructive pulmonary diseases (COPD). Since its incorporation in 1995 and subsequent name change in December 2013, Pulmonx has been at the forefront of offering innovative solutions for emphysema patients across various regions including the United States, Europe, the Middle East, Africa, the Asia-Pacific, and other international territories. The company's mission is to improve the quality of life for people suffering from severe respiratory conditions through their state-of-the-art medical devices. Headquartered in Redwood City, California, Pulmonx stands as a pivotal player in the respiratory care domain, continuously pushing the boundaries of medical technology for the betterment of patient outcomes.
Products and Services
- Zephyr Endobronchial Valve
A cornerstone of Pulmonx's product lineup, the Zephyr Endobronchial Valve offers an advanced solution for patients grappling with hyperinflation due to severe emphysema. This device is designed to alleviate the breathing difficulties associated with emphysema by controlling air flow and reducing lung volume, thereby enhancing respiratory efficiency and overall patient comfort.
- Chartis Pulmonary Assessment System
The Chartis System comprises a sophisticated balloon catheter and console equipped with state-of-the-art flow and pressure sensors. Its primary function is to conduct a precise assessment of the presence of collateral ventilation in the lung. This critical evaluation helps determine the suitability of patients for the Zephyr valve treatment, ensuring that only those who stand to benefit the most are selected for the procedure.
- StratX Lung Analysis Platform
An innovative cloud-based service, the StratX Platform revolutionizes the treatment planning process for emphysema by utilizing quantitative computed tomography analysis. The platform provides in-depth insights into emphysema destruction levels, fissure completeness, and lobar volume, which are integral in identifying the most appropriate target lobes for Zephyr Valve treatment. Through this personalized approach, healthcare providers can achieve a higher level of precision and effectiveness in managing emphysema, leading to better outcomes for patients.
